We have shown that the activity of ERK1/2 kinases in AML is linked to the cell differentiation stage, irrespective of genetic alterations, i.e., the pattern of kinase pathway activity differs in CD34+/- populations. This evidence concerns the gene CD34 and acute myeloid leukemia.